ATRALIN Drug Patent Profile
✉ Email this page to a colleague
When do Atralin patents expire, and when can generic versions of Atralin launch?
Atralin is a drug marketed by Dow Pharm and is included in one NDA.
The generic ingredient in ATRALIN is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the tretinoin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atralin
A generic version of ATRALIN was approved as tretinoin by PADAGIS US on December 24th, 1998.
Summary for ATRALIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 140 |
Clinical Trials: | 6 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ATRALIN |
What excipients (inactive ingredients) are in ATRALIN? | ATRALIN excipients list |
DailyMed Link: | ATRALIN at DailyMed |
Recent Clinical Trials for ATRALIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Zeichner, Joshua, M.D. | Phase 4 |
Johns Hopkins University | Phase 2 |
Bausch Health Americas, Inc. | Phase 3 |
Pharmacology for ATRALIN
Drug Class | Retinoid |
Anatomical Therapeutic Chemical (ATC) Classes for ATRALIN
US Patents and Regulatory Information for ATRALIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dow Pharm | ATRALIN | tretinoin | GEL;TOPICAL | 022070-001 | Jul 26, 2007 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ATRALIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Dow Pharm | ATRALIN | tretinoin | GEL;TOPICAL | 022070-001 | Jul 26, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ATRALIN
See the table below for patents covering ATRALIN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Portugal | 93638 | ⤷ Try a Trial | |
Norway | 901657 | ⤷ Try a Trial | |
Czechoslovakia | 9001911 | ⤷ Try a Trial | |
China | 1047802 | ⤷ Try a Trial | |
Hungary | T53518 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ATRALIN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1304992 | 122013000081 | Germany | ⤷ Try a Trial | PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322 |
1304992 | 1390049-3 | Sweden | ⤷ Try a Trial | PRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322 |
1304992 | PA2013025 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323 |
0617614 | 2001/009 | Ireland | ⤷ Try a Trial | PRODUCT NAME: PANRETIN-ALITRETINOIN |
1304992 | 92401 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |